This lack of specificity in standard treatments can be overcome by selecting, for instance, the substance P receptor; this is identical to the neurokinin type 1 receptor (NK1R) [18,19], which is almost exclusively expressed in the CNS compartment in pathological conditions, such as inflammation, trauma, or neoplasia. This evidence concerns the gene TACR1 and neoplasm.